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REQUESTED COMMENT CONCERNING: LIDOFLAZINE 
Willem Flameng, MD, Leuven, Belgium 
Lidoflazine is a drug that was developed by the Janssen 
Research Laboratories (Janssen Pharmaceutics, Beerse, 
Belgium) several decades ago but never became available 
on the international market. It has strong nucleoside 
transport inhibitory properties and can be classified as an 
ARA or adenosine regulating agent. 1Recently, there has 
been increasing interest in this type of drugs for myocar- 
dial protection, because they all enhance the tissue con- 
tent of adenosine in the myocardium. Adenosine is widely 
known for its cardioprotective properties against ischemic 
damage. 2 Accumulation of adenosine in the myocardium 
can be obtained by prevention of its breakdown (for 
example, by inhibition of its transport from the myocyte to 
the endothelial cell where adenosine is catabolized) or by 
stimulating its production. The latter can be done by 
infusing the precursor AICA riboside (5-amino-4-imida- 
zole carboxamide riboside). This drug is now under clin- 
ical investigation in large multicenter studies in the 
United States, Canada, and Europe. 
The study of Akpinar, Vanerman, and Wellens is 
interesting in so far as it demonstrates that extensive 
coronary bypass grafting can safely be done on the 
fibrillating heart using one single period of aortic cross- 
clamping combined with lidoßazine pretreatment. The 
clinical outcome was the same as when cardioplegia was 
used. However, the study does not provide scientific proof 
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for the cardioprotective properties of lidoflazine because 
the study was not placebo controlled. I realize, however, 
that a placebo-controlled study is unethical because pro- 
longed uninterrupted periods of ischemia, mainly on the 
fibrillating heart, will cause considerable myocardial dam- 
age. 3 The lack of significant release of creatine ldnase-MB 
as reported by Akpinar's group and the excellent clinical 
outcome suggest that myocardial injury is virtually absent 
in this setting. Although there is experimental evidence 
that lidoflazine will prevent myocardial damage ven after 
1 hour of normothermic global myocardial ischemia, 4 
these data cannot be extrapolated as such to the clinical 
situation and the diseased human heart. Therefore, I
believe that the technique described by Akpinar's group 
should not be advocated as generally applicable. Fast and 
skillful surgeons can use this technique, but they should 
realize that they might be balancing on a slack rope. 
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FIRST CLINICAL USE OF A HEPARIN REMOVAL DEVICE: AN ALTERNATIVE TO PROTAMINE 
Vincent R. Conti, MD, Roger A. Vertrees, BA, CCP, Joseph B. Zwischenberger, MD, and Mark Kurusz, CCP, 
Galveston, Tex. 
The reversal of heparin with protamine sulfate after 
termination of cardiopulmonary b pass (CPB) can elicit 
severe life-threatening reactions. These reactions can 
From the Division of Cardiothoracic Surgery, The University of 
Texas Medical Branch, Galveston, Tex. 
J THORAC CARDIOVASC SURG 1995;109:1015-7 
Copyright © 1995 by Mosby-Year Book, Inc. 
0022-5223/95 $3.00 + 0 12/8/58207 
occur despite such precautions as using a test dose of 
protamine, slow injection into the arterial side of the 
circulation, and premedication with steroids or H-l/H-2 
blockers. The adverse reactions occur more frequently in 
patients previously exposed to protamine, such as patients 
having second cardiac operations, patients with diabetes 
who receive neutral protamine Hagedorn (NPH) insulin, 
and patients with preoperative pulmonary hyperten- 
sion. As an alternative to protamine administration, the 
Heparin Removal Device was developed by Research 
